The approval of amyloid-targeting monoclonal antibodies by the MHRA marked a clear regulatory and scientific milestone in Alzheimer’s disease treatment. These agents demonstrated that disease-modifying intervention is possible at scale, rather than confined to experimental settings. However, by early 2026, consensus across the pharmaceutical and clinical research community had shifted. The magnitude of benefit observed in late phase trials, typically a slowing of functional decline in the range of 27% to 35% over an 18-month period, has been judged meaningful but insufficient when weighed against cost, complexity, and the incidence of amyloid-related imaging abnormalities. As a result, amyloid removal is now widely framed as a foundational intervention rather than a complete therapeutic solution.
The primary benefit of amyloid clearance is increasingly understood as enabling downstream mechanisms to operate more effectively. Rather than halting neurodegeneration on its own, amyloid reduction may reduce pathological burden sufficiently to allow anti-tau, anti-inflammatory, and neuroprotective strategies to exert clinically relevant effects. This interpretation, discussed extensively at CTAD 2025, reflects a broader recalibration of expectations. Alzheimer’s disease is no longer approached as a single target disorder, but as a multifactorial condition requiring coordinated intervention across several biological pathways.
Why amyloid monotherapy shows diminishing returns
Amyloid-directed therapies achieved regulatory approval on the basis of consistent biomarker effects and modest clinical slowing. However, their limitations are now better characterised. Removal of amyloid plaques does not directly address tau aggregation, synaptic dysfunction, neuroinflammation, vascular pathology, or downstream neuronal loss. These processes continue to evolve even when the amyloid burden is substantially reduced.
In addition, the safety profile of amyloid antibodies has constrained their clinical deployment. Amyloid-related imaging abnormalities, including vasogenic oedema and microhaemorrhage, require repeated imaging, specialist oversight, and careful patient selection. These requirements introduce friction into routine clinical use and complicate large-scale NHS implementation.
From a development perspective, amyloid monotherapy has also exposed the ceiling of single-mechanism approaches in neurodegeneration. While biologically rational, targeting one pathological hallmark has not translated into disease stabilisation. This has reinforced the view that amyloid clearance is best positioned as an enabling step rather than a definitive endpoint.
The shift towards multi-target drug strategies
Drug development pipelines in 2025 and 2026 increasingly reflect this reframing. Current estimates indicate approximately 138 novel agents in clinical trials for Alzheimer’s disease, with a growing proportion designed to engage more than one pathological pathway. This includes multi-target directed ligands, gene silencing approaches, and rational combinations of biologics and small molecules.
Multi-target directed ligands are single chemical entities engineered to modulate multiple disease-relevant mechanisms simultaneously. Their appeal lies in reducing the need for complex combination regimens while addressing the interconnected biology of neurodegeneration. Rather than stacking monotherapies, these compounds aim to deliver coordinated modulation within one pharmacokinetic and safety profile.
This approach reflects lessons learned from oncology and infectious disease, where single-target interventions often fail in the face of adaptive or multifactorial pathology. In Alzheimer’s disease, the convergence of amyloid, tau, synaptic dysfunction, inflammation, and vascular compromise presents a similar challenge.
Buntanetap as a triple pathway candidate
Buntanetap represents one of the most closely watched multi-target candidates entering late-stage development in 2026. The compound is designed to inhibit the synthesis of amyloid beta, tau, and alpha synuclein at the translational level. This triple pathway approach reflects the recognition that overlapping proteinopathies contribute to disease progression and clinical heterogeneity.
From a mechanistic standpoint, reducing the production of these proteins upstream may offer advantages over clearance-based strategies. By limiting new pathological accumulation, buntanetap aims to slow the reinforcement of toxic cascades that persist even after amyloid plaques are removed.
Phase III development has positioned buntanetap as a test case for whether a single small molecule can meaningfully influence multiple disease drivers without unacceptable off-target effects. Its progress is being closely monitored by regulators and payers as a potential alternative to antibody-heavy pipelines.
Gene silencing approaches targeting tau
Alongside small molecule innovation, gene silencing strategies have emerged as a distinct pillar of post-amyloid development. BIIB080, developed through Ionis and Biogen collaboration, represents the first antisense oligonucleotide designed to reduce tau production directly at the mRNA level.
Unlike amyloid antibodies, which act extracellularly, antisense therapies intervene upstream in protein synthesis. This offers a different risk-benefit profile, with the potential for sustained reduction in pathological tau expression following repeated dosing. Phase II trials underway at NIHR UCLH Clinical Research Facility have positioned BIIB080 as a proof of principle for disease modification beyond amyloid.
Gene silencing approaches also raise important considerations for long-term safety, dosing durability, and patient selection. Their inclusion in the pipeline reflects confidence that Alzheimer’s disease can be addressed at the level of gene expression, not only protein aggregation.
Molecular hybrids and enzyme modulation
Early 2026 research has also highlighted renewed interest in molecular hybrid compounds. These agents combine structural features that allow simultaneous modulation of acetylcholinesterase, beta-secretase, and oxidative stress pathways. Examples include lipocrine hybrids and 8-hydroxyquinoline derivatives.
While these compounds remain earlier in development, they illustrate continued effort to integrate symptomatic and disease-modifying effects within a single molecule. By combining neurotransmitter support with amyloid pathway modulation and antioxidant protection, these hybrids aim to bridge the historical divide between symptomatic treatment and disease modification.
Their progress remains contingent on demonstrating sufficient central nervous system penetration and acceptable safety margins, but they contribute to the broader narrative that Alzheimer’s pharmacology is moving beyond single-axis intervention.
London as a centre for multi-target clinical research
London continues to play a central role in testing these emerging strategies. The Dementia Research Centre at Queen Square has become a focal point for trials reflecting the shift towards multi-target and mechanism-diverse approaches. Its integration of neurology, imaging, biomarker analysis, and clinical pharmacology provides an environment suited to complex study designs.
Several programmes underway in 2026 illustrate this positioning. Studies evaluating microglial modulation, vascular inflammation, and blood-brain barrier transport technologies are being conducted in parallel, rather than sequentially. This reflects a willingness to explore multiple biological hypotheses concurrently.
The concentration of expertise and infrastructure in London supports rapid translation from early-phase data to later-stage evaluation, while maintaining rigorous oversight.
Targeting neuroinflammation through microglial pathways
Neuroinflammation has emerged as a critical contributor to disease progression, particularly in later stages. Novartis VHB937 represents an approach aimed at modulating microglial activity rather than suppressing inflammation globally. By targeting immune signalling pathways implicated in chronic neuroinflammatory states, this strategy seeks to reduce secondary neuronal damage.
Microglial modulation reflects a more nuanced understanding of neuroinflammation, recognising that immune responses in the brain can be both protective and harmful depending on context. Therapies in this class are being evaluated for their ability to restore homeostatic immune function rather than blunt inflammation indiscriminately.
Improving amyloid delivery across the blood-brain barrier
Even as amyloid monotherapy reaches its limits, delivery innovation continues to refine its role within combination strategies. Roche trontinemab employs a brain shuttle platform designed to enhance transport across the blood-brain barrier. By increasing central exposure at lower systemic doses, this technology aims to reduce the incidence of amyloid-related imaging abnormalities.
If successful, improved delivery could reposition amyloid antibodies as lower-risk components within multi-target regimens. Rather than high-dose standalone agents, they may function as preparatory or maintenance therapies alongside tau, inflammatory, or synaptic interventions.
Addressing vascular pathology and fibrin-driven inflammation
Vascular contributions to cognitive impairment and dementia have gained increased attention, particularly in patients with mixed pathology. THN391 targets inflammatory epitopes of fibrin, aiming to reduce vascular-driven neuroinflammation in individuals with Alzheimer’s disease and cerebral small vessel disease.
This approach reflects growing recognition that vascular pathology interacts with amyloid and tau to accelerate neurodegeneration. Addressing fibrin-mediated inflammation may therefore complement other disease-modifying strategies, particularly in populations underrepresented in earlier trials.
Regulatory reform supporting complex therapeutic pathways
The delivery of multi-target therapies is closely linked to regulatory infrastructure. The MHRA and NICE Aligned Pathway, scheduled for full implementation in April 2026, is intended to synchronise regulatory approval and health technology assessment processes. By enabling parallel evaluation, this framework aims to reduce delays between marketing authorisation and NHS access.
For complex regimens involving multiple agents or novel mechanisms, aligned assessment is particularly important. Sequential evaluation risks fragmenting evidence and delaying patient access, whereas coordinated review can support more coherent decision making.
In parallel, the Medicines for Human Use Clinical Trials Regulations 2025 introduce mandatory transparency and public registration requirements from April 2026. These changes strengthen public trust and data integrity, while reinforcing the evidentiary standards expected of UK-based research.
Implications for evidence generation and trial design
Regulatory reform also influences trial methodology. Multi-target strategies require adaptive designs capable of evaluating interactions between agents and pathways. Biomarker-driven stratification, platform trials, and long-term follow-up are becoming standard rather than exceptional.
For Alzheimer’s disease, this means moving beyond short-duration cognitive endpoints towards integrated outcome frameworks incorporating imaging, fluid biomarkers, functional measures, and real-world data. The regulatory environment in the UK is increasingly aligned with this complexity, although implementation will require sustained investment.
The expanding clinical role of the pharmacist
As therapeutic strategies become more complex, the role of the pharmacist is evolving accordingly. In 2026, pharmacists are increasingly embedded within multidisciplinary dementia care teams, contributing to treatment selection, monitoring, and optimisation.
One emerging responsibility is biomarker interpretation. With the rollout of blood-based p tau217 diagnostic pilots, pharmacists are expected to understand assay limitations, predictive value, and eligibility implications for specific trials or treatments. This represents a shift from traditional dispensing roles towards clinical decision support.
Managing combination therapy and polypharmacy
The transition to multi-target regimens increases the risk of polypharmacy-related harm. Pharmacists are central to managing drug interactions, assessing cumulative adverse effect burden, and identifying opportunities to deprescribe symptomatic agents that no longer provide benefit.
This role is particularly important in older populations with comorbidities, where background medication load is already high. Precision pharmacology in this context requires both mechanistic understanding and practical clinical judgement.
Monitoring adverse reactions in advanced therapies
Monitoring for adverse drug reactions remains a core responsibility, but the nature of those reactions is changing. Amyloid-related imaging abnormalities, infusion reactions, and immune-mediated effects associated with biologics require specialised knowledge and coordination with imaging and neurology services.
Pharmacists play a key role in surveillance, reporting, and patient education, ensuring that safety signals are detected early and managed appropriately.
Conclusion
The period following amyloid antibody approval has clarified both the potential and the limits of single-target intervention in Alzheimer’s disease. By early 2026, the field had largely accepted that amyloid removal alone is insufficient to halt disease progression. Instead, it is increasingly viewed as a preparatory step within broader, multi-target strategies.
London’s research ecosystem reflects this shift, with clinical programmes spanning protein synthesis inhibition, gene silencing, immune modulation, vascular targeting, and delivery optimisation. Regulatory reform in the UK is evolving in parallel, aiming to accommodate the complexity of these approaches while maintaining rigorous standards of evidence and transparency.
For the pharmaceutical sector, this transition represents maturation rather than failure. Moving beyond amyloid does not negate its relevance, but reframes it within a more realistic understanding of neurodegenerative biology. The challenge ahead lies in integrating these diverse mechanisms into coherent, accessible treatment pathways that deliver meaningful benefit to patients while remaining sustainable for the NHS.
